We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us


EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App

Multiparameter Autoantibody Detection Aids Diagnosis of Myositis

By LabMedica International staff writers
Posted on 12 Jul 2023
Print article
Image: EUROBlotOne for fully automated immunoblot analyses (Photo courtesy of EUROIMMUN)
Image: EUROBlotOne for fully automated immunoblot analyses (Photo courtesy of EUROIMMUN)

Idiopathic inflammatory myopathies (IIM), or myositides, are a collection of systemic autoimmune rheumatic diseases. These disorders are characterized by chronic inflammation of the skeletal muscle, and in some instances, can be linked to cancer. Due to their rarity, resemblance to other rheumatic diseases, and the potential for overlap syndromes, diagnosing IIMs can be complex. Pinpointing the exact subtype of the disease is crucial due to diverse treatment options. Autoantibodies are critical diagnostic biomarkers for IIM and help in identifying disease subtypes. The German Society for Neurology (DGN) issued guidelines in 2022, mandating the identification of myositis-specific autoantibodies (MSA) and myositis-associated autoantibodies (MAA) as a diagnostic step. Given the low prevalence and frequent isolation of IIM autoantibodies, antibody detection must be as comprehensive as possible.

EUROIMMUN (Lübeck, Germany) has developed a line blot (EUROLINE Autoimmune Inflammatory Myopathies 20 Ag Profile) that uniquely combines 20 nuclear and cytoplasmic antigens. This assists in detecting and differentiating autoantibodies in IIM, making it the most comprehensive commercially available line blot for IIM diagnostics. The antigen portfolio encompasses the MSA target antigens Zo, Ks, Ha, cN-1A, OJ, EJ, PL-12, PL-7, SRP, Jo-1, SAE1, NXP2, MDA5, TIF1γ, Mi-2α and Mi-2β and the MAA target antigens Ku, PM-Scl75, PM-Scl100 and Ro-52, each printed onto separate membrane chips for optimal antibody detection efficiency. The immunoblot analysis is particularly effective in identifying autoantibodies against cytoplasmic antigens, which other methods such as indirect immunofluorescence can miss. The assay process and result evaluation can be fully automated.

This specific antibody detection approach aids in diagnosing IIM subforms in light of clinical symptoms. Notably, anti-cN-1A is the sole known serological marker for sporadic inclusion body myositis (sIBM). Since anti-cN-1A is rarely found in other IIMs, its detection can help distinguish sIBM from other IIM forms, aiding in early diagnosis. The EUROLINE is the sole commercial line blot that includes this antigen. The antigens Zo, Ks, and Ha supplement the tRNA synthetase antigen spectrum for differential diagnosis of anti-synthetase syndrome (ASS) along with EJ, OJ, PL-12, PL-7, Jo-1, and SRP. Current research is exploring the link of antibodies against Zo, Ks, and Ha with interstitial lung disease. Autoantibodies against Mi-2α, Mi-2β, NXP2, TIF1γ, SAE1, and MDA5 are indicative of dermatomyositis (DM), with anti-NXP2 and anti-TIF1γ often associated with malignancies. Antibodies against Ku, PM-Scl-75, and PM-Scl100 are typically found in overlap syndromes, while anti-SRP is present in necrotizing myositis. Detecting specific autoantibodies can significantly accelerate diagnosis, enabling prompt therapeutic intervention. Autoantibody profiling also helps in assessing malignancy risk and predicting therapy outcomes.

Related Links:

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article


Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.